All In Biotech

Drug Trial Radar · NCT07603713

Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe Periodontitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅱ Study to Evaluate the Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe Periodontitis

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Nov 12, 2026

Study completion Mar 23, 2027

Sponsor

Sponsor type
Industry
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the clinical efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple local injections of different doses of LP-005 injection in patients with moderate-to-severe periodontitis, and to investigate changes in biomarker levels.

Conditions

  • Periodontitis

Interventions

  • LP-005 InjectionDrug

    LP-005 is a bifunctional antibody fusion protein consisting of an anti-human C5 monoclonal antibody and a human complement regulatory protein, formulated as a sterile injectable solution. Each vial contains 300 mg of LP-005 in 6 mL (50 mg/mL). The LP-005 is administered via interdental papilla injection.

  • Placebo InjectionDrug

    Placebo is a sterile injectable solution matched to LP-005 for appearance, formulation, and administration, with 0 mg of active ingredient per 6 mL vial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Gingival Index (GI)Time frame: Day 43, Day 85, Day 127, and Day 169
  2. Change from Baseline in Bleeding Index (BI)Time frame: Day 43, Day 85, Day 127, and Day 169
  3. Change from Baseline in Probing Pocket Depth (PD)Time frame: Day 43, Day 85, Day 127, and Day 169
  4. Change from Baseline in Clinical Attachment Loss (AL)Time frame: Day 43, Day 85, and Day 127, Day 169
  5. Change from Baseline in Plaque Index (PI)Time frame: Day 43, Day 85, Day 127, and Day 169
  6. Change from Baseline in Alveolar Bone Defect HeightTime frame: Day 85, and Day 169
  7. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 24 weeks
  8. Detect Pharmacokinetic (PK) Characteristics of LP-005Time frame: Up to approximately 24 weeks
  9. Gingival Crevicular Fluid (GCF) Concentration of LP-005Time frame: Up to approximately 24 weeks
  10. Detect Pharmacodynamics (PD) Characteristics of LP-005Time frame: Up to approximately 24 weeks
  11. Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) AssessmentTime frame: Up to approximately 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University School and Hospital of Stomatology

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.